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Objectives: To perform MRI cerebellum volumetry in patients exposed to phenytoin and to identify factors associated with
cerebellar atrophy (CA).
Methods: From 100 consecutive epilepsy patients we selected those with phenytoin use for more than 2 months and with MRI
scan available for volumetric studies. We obtained cerebellar volumes corrected for total intracranial volume. Volumes below 2
standard deviations from the mean of control group were considered abnormal.
Results: We studied 56 patients (33 women). Mean age was 33.6 years and mean duration of epilepsy was 17.6 years. Mean
daily dose of phenytoin was 301 mg. CA was detected in 20 (35.7%) patients. CA was not associated with frequent generalised
seizures. CA correlated with duration of epilepsy (r = −0.34; P = 0.01) and years of treatment with phenytoin (r = −0.48;
P = 0.001), but not with age and mean daily dosage of phenytoin (P > 0.05). However, a multiple correlation analysis as
well as a backward stepwise multiple regression analysis including all variables showed that only duration of treatment was
significantly associated with CA (P = 0.001).
Conclusions: CA is frequently associated with long-term use of phenytoin. Although duration of epilepsy may have an influence
in the CA, this is clearly less important than the time of exposure to phenytoin.
© 2002 BEA Trading Ltd. Published by Elsevier Science Ltd. All rights reserved.
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INTRODUCTION
Phenytoin is one of the first line antiepileptic drugs
(AEDs) for many epilepsy syndromes. High effi-
cacy for partial as well as generalised seizures and
low cost contributes to its widespread use. As with
other commonly used AEDs, adverse effects can
be frequently identified and sometimes lead to drug
discontinuation1. One of most important adverse
effect observed in phenytoin use is the cerebellar tox-
icity, associated with ataxia, tremor, nystagmus and
diplopia1. Cerebellar atrophy (CA) may be observed
in phenytoin-exposed patients with epilepsy in the
absence of generalised tonic–clonic seizures (GTCS)
or pre-existent brain damage2, 3. Whether it is the
phenytoin2, 4–8, the seizures2, 9 or the initial brain
insult10 that play the primary aetiologic role in CA, it
remains unclear3, 11, 12.
The aim of this study was to investigate whether
cerebellar volumes of patients exposed to long-term
use of phenytoin or other variables are associated to
CA.
PATIENTS AND METHODS
Ascertainment of subjects
We selected 100 consecutive epilepsy patients fol-
lowed in our epilepsy clinic who had MRI scan avail-
able for cerebellar volumetric studies. We then ex-
cluded patients who used phenytoin for less than 2
months, patients who had status epilepticus, severe
head trauma or meningitis, and those with insufficient
available clinical data.
All patients included in this study signed a written
informed consent for research protocol, approved by
the Ethics Committee of our medical school.
We collected clinical data, including age at seizure
onset, duration of epilepsy (defined here as duration
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of recurrent seizures), epilepsy syndrome, risk factors,
dosage and duration of phenytoin treatment, and fre-
quency of GTCS. Although we ascertained frequency
of GTCS by seizure calendars, it is well known that
seizure frequency is not a highly reliable measure.
None of the patients evaluated here were completely
seizure-free and the majority were candidates for sur-
gical treatment.
MRI studies
MRI scans were obtained in a 2 T scanner (Elscint
Prestige®), with acquisitions in three orthogonal
planes (axial, sagital and coronal). We used 6 mm
slices sagital T1 acquisition for cerebellar measure-
ments (T1 spin echo, 6 mm thick, flip angle = 180◦;
repetition time (TR) = 430, echo time (TE) =
12, matrix 200 × 350, field of view (FOV) =
25 cm× 25 cm, interslice gap of 0.6 mm).
Images were transferred to a PC and saved as stacks
in TIFF format. We used Scion Image program® for
manual delineation of cerebellar areas and total in-
tracranial volumes (TIV), for each subject (all the seg-
mentations were performed by one examiner). TIV
were obtained by outlining the external boundaries of
the brain in sagital slices (excluding cerebellum and
brain stem) and calculating the sum of all cross-section
areas. We calculated the total cerebellar volume by
multiplying the total area from all cerebellar slices by
the width (6 mm) and then normalised it by the TIV
as follows: normalised cerebellar volume = patient’s
cerebellar volume/patient’s TIV.
Twenty healthy adult volunteers, from laboratory
personnel, were used as the control group in this study
(mean age = 30.1 years, ranging from 22 to 62 years).
None of them had any medical problem.
Cerebellar volumes were transformed into Z-scores
(standardised scores that express the number of stan-
dard deviations away from the mean of the control
group) to facilitate interpretation of severity of atro-
phy in individual patients. Volumes below−2 standard
deviation (SD) from the mean of control group were
considered abnormal. CA was classified in mild (−2
to −3 SD), moderate (−3 to −4 SD) and severe (be-
low −4 SD) according to the Z-scores obtained from
each patient.
Statistical analyses
We performed Pearson’s correlation analysis and
a backward stepwise multiple regression analysis
to determine the most significant correlation. Chi-
square test and ANOVA were performed whenever
appropriate.
RESULTS
A total of 56 patients were studied (33 women). Mean
present age was 33.6 years (ranging from 4 to 65 years)
and age at seizure onset varied from 1 to 64 years
(mean = 16 years). Duration of epilepsy ranged from
1 to 41 years (mean = 17.6 years). One patient had
primary generalised epilepsy, 43 had temporal lobe
epilepsy and 12 had partial extra-temporal epilepsy.
History of alcohol consumption was positive in 12
(21.5%) patients, earlier febrile seizures in 10 (18%)
and signs of phenytoin intoxication were previously
observed in 16 (28.5%) patients.
Mean daily dose of phenytoin was 301 mg (ranging
from 100 to 650 mg). Blood serum levels of pheny-
toin were available in 18 patients, with toxic levels in
9 patients. Frequency of GTCS, obtained by seizure
calendars, was available in 55 patients: 25 never had
GTCS or were seizure-free for at least 2 years, 2 had
daily GTCS, 22 had 1–3 GTCS per month, 2 patients
had 5–15 GTCS per month and 5 patients had spo-
radic GTCS, once or twice per year.
CA was observed in 20 (35.7%) patients: 9/20 (45%)
had mild atrophy (Z-scores from −2 to −3), 9/20
(45%) had moderate atrophy (Z-scores from −3 to
−4) and 2/20 (10%) had severe atrophy (Z-scores be-
low −4). Destructive pre-existing brain damage, re-
lated to perinatal insults, were observed in 5 patients,
but none of them had CA.
CA was not significantly associated with history of
alcohol intake or febrile seizures in this group of pa-
tients, as it occurred in only 2/12 (16.6%) of those with
alcoholism and 2/10 (20%) patients with earlier febrile
seizures. However, it was identified in 9/16 (56%) pa-
tients who had had clinical evidences of phenytoin
intoxication.
GTCS did not occur more frequently in patients
with CA as compared to those without atrophy: 12/20
(60%) had never had GTCS or were seizure-free for at
least 2 years, whereas 8/20 (40%) had at least 1 GTCS
per month (2 patients had frequent GTCS, up to 6 per
month in 1 and up to 15 per month in the remaining
patient).
Cerebellar volumes were similar in patients with fre-
quent GTCS and with rare GTCS (ANOVA, F [1] =
0.164, P = 0.68). In addition, there was no difference
regarding frequency of GTCS between patients with
and without CA (Pearson’s Chi-square, P = 0.74).
CA correlated with duration of epilepsy (r = −0.34;
P = 0.01) and duration of treatment with phenytoin
(r = −0.48; P = 0.001), but not with age, age at
seizure onset, maximum dosage used and mean daily
dosage of phenytoin (P > 0.05). However, when in-
cluding all variables in a multiple correlation analysis
(excluding age at seizure onset, as this is a variable that
confounds with duration of epilepsy), only duration
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of treatment with phenytoin variable was significantly
correlated with CA (r = −0.46; P = 0.01). A back-
ward stepwise multiple regression analysis confirmed
that duration of treatment with phenytoin was the vari-
able most correlated with CA (P = 0.001).
DISCUSSION
There are several reports of cerebellar toxicity related
to phenytoin and neuroimaging studies have focused
on visual assessment of CA2, 3, 12, 13.
In a previous study5, we evaluated CA by CT scan
in 66 consecutive patients with epilepsy followed in
a tertiary epilepsy centre. Patients were divided into
two groups, those who used phenytoin and those who
did not. Of the 66 patients studied, 18 (27%) had mod-
erate/severe atrophy, 15 (23%) had mild atrophy and
33 (50%) were considered normal. Patients with mod-
erate/severe atrophy were those with longer exposure
to phenytoin (longer duration of treatment and higher
total dosage) showing statistically significant differ-
ence when compared to patients with mild atrophy
or without atrophy. In addition, patients with moder-
ate/severe CA had serum levels of phenytoin statisti-
cally higher than those of patients with mild atrophy
or without atrophy. There was no association between
other AED dosage or duration of treatment and degree
of CA.
We also found that older patients had CA more fre-
quently, indicating that age or duration of the seizure
disorder could also be important in the determination
of cerebellar degeneration in these patients5. Simi-
lar findings have been reported by other studies2, 3, 12,
however, data derived from qualitative analyses of CA
do not allow more robust statistical correlations and
make interpretation of results difficult.
MRI-based cerebellar volumetric measurements
allow objective evaluation of less severe, usually
asymptomatic CA, and provide numerical data that
can be correlated with several other variables and
may be used for monitoring progression of atrophy.
Two previous studies reported CA by volumetric
measurements after phenytoin intoxication11, 14. Luef
et al.11 concluded that phenytoin overdosage does not
necessarily result in CA. However, they included only
11 patients who had experienced clinical intoxication
with phenytoin.
In the present study we confirmed that CA is fre-
quently associated with long-term use of phenytoin.
This is corroborated by the finding of more severe
atrophy in those patients who have had phenytoin in-
toxication. In this series, frequency of GTCS did not
influence the occurrence or severity of CA. Although
duration of epilepsy may have an influence in the
CA, this is clearly less important than the length of
exposure to phenytoin. It is also possible that duration
of epilepsy in this series confounded with duration
of treatment; i.e. patients with longer treatment with
phenytoin had longer duration of epilepsy and vice
versa. Otherwise, one would expect a correlation be-
tween CA and age of onset as well as with duration
of epilepsy. Multiple correlation analysis and a back-
ward stepwise multiple regression analysis confirmed
that duration of treatment with phenytoin was the
variable most correlated with CA.
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